Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ

Journal of Neural Transmission

Volumn 122, Issue 7, 2015, Pages 1069-1076

  Strobel, S ^a   Grunblatt E ^b   Riederer, P ^a   Heinsen, H ^a   Arzberger, T ^c,f   Al Sarraj, S ^d   Troakes, C ^d   Ferrer, I ^e   Monoranu, Camelia Maria ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CX3CL1; Neuroinflammation; PPAR ; Sporadic Alzheimer s disease; TREM2

Indexed keywords

FRACTALKINE; MEMBRANE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL 2; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; CXCL3 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; TREM2 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BONE MARROW CELL; BRAIN REGION; BRAIN STEM; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFERIOR OLIVE; MALE; MEDULLA OBLONGATA; MIDDLE AGED; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TRIGEMINAL NUCLEUS; VAGUS NERVE; VERY ELDERLY; ANALYSIS OF VARIANCE; BRAIN; CASE CONTROL STUDY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; CHEMOKINES, CXC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PPAR GAMMA; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER;

EID: 84937468720     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-015-1369-5     Document Type: Article

References (35)

1. Aguzzi A, Barres BA, Bennett ML (2013) Microglia: scapegoat, saboteur, or something else? Science 339(6116):156–161. doi:10.1126/science.1227901
2. Aleshin S, Reiser G (2013) Role of the peroxisome proliferator-activated receptors (PPAR)-alpha, beta/delta and gamma triad in regulation of reactive oxygen species signaling in brain. Biol Chem 394(12):1553–1570. doi:10.1515/hsz-2013-0215
3. Attems J, Thomas A, Jellinger K (2012) Correlations between cortical and subcortical tau pathology. Neuropathol Appl Neurobiol 38(6):582–590. doi:10.1111/j.1365-2990.2011.01244.x
4. Bartl J, Monoranu CM, Wagner AK, Kolter J, Riederer P, Grunblatt E (2013) Alzheimer’s disease and type 2 diabetes: two diseases, one common link? World J Biol Psychiatry 14(3):233–240. doi:10.3109/15622975.2011.650204
5. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644. doi:10.1038/385640a0
6. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
7. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121(2):171–181. doi:10.1007/s00401-010-0789-4
8. Braak H, Braak E, Bohl J, Lang W (1989) Alzheimer’s disease: amyloid plaques in the cerebellum. J Neurol Sci 93(2–3):277–287
9. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer’s disease. Neurobiol Dis 37(3):503–509. doi:10.1016/j.nbd.2009.10.006
10. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917–924
11. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 4(4):399–418. doi:10.1007/s11481-009-9164-4
12. Fallgatter AJ, Neuhauser B, Herrmann MJ, Ehlis AC, Wagener A, Scheuerpflug P, Reiners K, Riederer P (2003) Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm 110(12):1437–1443. doi:10.1007/s00702-003-0087-6
13. Fallgatter AJ, Ehlis AC, Ringel TM, Herrmann MJ (2005) Age effect on far field potentials from the brain stem after transcutaneous vagus nerve stimulation. Int J Psychophysiol 56(1):37–43
14. Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, Levine AP, Hardy J, Pocock JM, Guerreiro R, Weale ME, Ryten M (2013) Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging 34(12):2699–2714. doi:10.1016/j.neurobiolaging.2013.05.001
15. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94(9):4312–4317
16. Grinberg LT, Rueb U, Heinsen H (2011) Brainstem: neglected locus in neurodegenerative diseases. Front Neurol 2:42. doi:10.3389/fneur.2011.00042
17. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 28(3):327–335
18. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU (2002) Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 69(3):418–426. doi:10.1002/jnr.10304
19. Hickman SE, El Khoury J (2014) TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88(4):495–498. doi:10.1016/j.bcp.2013.11.021
20. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109(4):1144–1156. doi:10.1111/j.1471-4159.2009.06042.x
21. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, Lee CU (2008) Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 436(2):196–200. doi:10.1016/j.neulet.2008.03.019
22. Larner AJ (1997) The cerebellum in Alzheimer’s disease. Dement Geriatr Cogn Disord 8(4):203–209
23. Lue LF, Schmitz C, Walker DG (2014a) What happens to microglial TREM2 in Alzheimer’s disease: Immunoregulatory turned into immunopathogenic? Neuroscience. doi:10.1016/j.neuroscience.2014.09.050
24. Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG (2014b) TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. doi:10.1111/bpa.12190
25. Mandrekar-Colucci S, Landreth GE (2011) Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets 15(9):1085–1097. doi:10.1517/14728222.2011.594043
26. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci 32(30):10117–10128. doi:10.1523/JNEUROSCI.5268-11.2012
27. Mavroudis IA, Fotiou DF, Adipepe LF, Manani MG, Njau SD, Psaroulis D, Costa VG, Baloyannis SJ (2010) Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer’s disease. Am J Alzheimers Dis Other Demen 25(7):585–591. doi:10.1177/1533317510382892
28. Nomura S, Mizuno N (1983) Central distribution of efferent and afferent components of the cervical branches of the vagus nerve. A HRP study in the cat. Anat Embryol (Berl) 166(1):1–18
29. Polak T, Ehlis AC, Langer JB, Plichta MM, Metzger F, Ringel TM, Fallgatter AJ (2007) Non-invasive measurement of vagus activity in the brainstem: a methodological progress towards earlier diagnosis of dementias? J Neural Transm 114(5):613–619. doi:10.1007/s00702-007-0625-8
30. Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W, Melik Parsadaniantz S (2013) Current status of chemokines in the adult CNS. Prog Neurobiol 104:67–92
31. Rosenthal SL, Kamboh MI (2014) Late-onset Alzheimer’s disease genes and the potentially implicated pathways. Curr Genet Med Rep 2:85–101. doi:10.1007/s40142-014-0034-x
32. Schwaeble WJ, Stover CM, Schall TJ, Dairaghi DJ, Trinder PK, Linington C, Iglesias A, Schubart A, Lynch NJ, Weihe E, Schafer MK (1998) Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett 439(3):203–207
33. Sheridan GK, Murphy KJ (2013) Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol 3(12):130181. doi:10.1098/rsob.130181
34. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201(4):647–657
35. Williamson LL, Bilbo SD (2013) Chemokines and the hippocampus: a new perspective on hippocampal plasticity and vulnerability. Brain Behav Immun 30:186–194. doi:10.1016/j.bbi.2013.01.077